IAVI、Minapharm和ProBioGen伙伴促进非洲当地生产天花和艾滋病毒疫苗,目的是增加获得疫苗的机会和自力更生。 IAVI, Minapharm, and ProBioGen partner to boost Africa’s local production of Mpox and HIV vaccines, aiming for greater access and self-reliance.

IAVI、Minapharm和ProBioGen建立了伙伴关系,以促进非洲的疫苗和生物生产,重点是天花和艾滋病毒。 IAVI, Minapharm, and ProBioGen have formed a partnership to boost Africa’s vaccine and biologic production, focusing on Mpox and HIV. 合作的目的是通过将国际艾滋病疫苗倡议的发展专长、米纳波尔在埃及的生产能力以及ProBioGen的先进疫苗技术结合起来,增加目前仅占非洲疫苗需求的1%的当地制造。 The collaboration aims to increase local manufacturing, currently at just 1% of Africa’s vaccine needs, by combining IAVI’s development expertise, Minapharm’s production capabilities in Egypt, and ProBioGen’s advanced vaccine technologies. 该倡议在非洲疾控中心、Wellcome Trust和KENUP非洲基金会的支持下,包括技术转让、能力建设和努力确保公平获得拯救生命的治疗。 Supported by Africa CDC, Wellcome Trust, and kENUP Africa Foundation, the initiative includes technology transfer, capacity building, and efforts to ensure equitable access to life-saving treatments.